LU92992I2 - Valsartan et amlodipine et leurs sels pharmaceutiquement acceptables - Google Patents
Valsartan et amlodipine et leurs sels pharmaceutiquement acceptables Download PDFInfo
- Publication number
- LU92992I2 LU92992I2 LU92992C LU92992C LU92992I2 LU 92992 I2 LU92992 I2 LU 92992I2 LU 92992 C LU92992 C LU 92992C LU 92992 C LU92992 C LU 92992C LU 92992 I2 LU92992 I2 LU 92992I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- pharmaceutically acceptable
- hypertension
- diabetic
- renal
- primary
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 3
- 229940043102 valsartan and amlodipine Drugs 0.000 title 1
- 206010020772 Hypertension Diseases 0.000 abstract 3
- 206010012601 diabetes mellitus Diseases 0.000 abstract 3
- 206010002383 Angina Pectoris Diseases 0.000 abstract 2
- 206010019280 Heart failures Diseases 0.000 abstract 2
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 2
- 201000006370 kidney failure Diseases 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010003658 Atrial Fibrillation Diseases 0.000 abstract 1
- 206010003662 Atrial flutter Diseases 0.000 abstract 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 abstract 1
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 208000007530 Essential hypertension Diseases 0.000 abstract 1
- 206010018364 Glomerulonephritis Diseases 0.000 abstract 1
- 206010020571 Hyperaldosteronism Diseases 0.000 abstract 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000003782 Raynaud disease Diseases 0.000 abstract 1
- 208000012322 Raynaud phenomenon Diseases 0.000 abstract 1
- 206010039710 Scleroderma Diseases 0.000 abstract 1
- 206010039808 Secondary aldosteronism Diseases 0.000 abstract 1
- 206010042600 Supraventricular arrhythmias Diseases 0.000 abstract 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 abstract 1
- 239000000480 calcium channel blocker Substances 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 206010061989 glomerulosclerosis Diseases 0.000 abstract 1
- 206010020718 hyperplasia Diseases 0.000 abstract 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 abstract 1
- 201000001474 proteinuria Diseases 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 abstract 1
- 229960004699 valsartan Drugs 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fats And Perfumes (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11389398A | 1998-07-10 | 1998-07-10 | |
| EP99934647A EP1096932B1 (fr) | 1998-07-10 | 1999-07-09 | Combinaison antihypertensive a base de valsartan et d'un bloquant du canal de calcium |
| EP07105179A EP1870098A3 (fr) | 1998-07-10 | 1999-07-09 | Utilisation combinée de valsaratan et bloqueurs du canal de calcium à buts thérapeutiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU92992I2 true LU92992I2 (fr) | 2016-05-09 |
Family
ID=22352165
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU91358C LU91358I2 (fr) | 1998-07-10 | 2007-09-06 | Combinaison antihypertensive a base de valsartan et d'un bloquant du canal de calcium |
| LU92992C LU92992I2 (fr) | 1998-07-10 | 2016-03-07 | Valsartan et amlodipine et leurs sels pharmaceutiquement acceptables |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU91358C LU91358I2 (fr) | 1998-07-10 | 2007-09-06 | Combinaison antihypertensive a base de valsartan et d'un bloquant du canal de calcium |
Country Status (31)
| Country | Link |
|---|---|
| EP (3) | EP1870098A3 (fr) |
| JP (1) | JP2002520274A (fr) |
| KR (2) | KR100550167B1 (fr) |
| CN (2) | CN1234357C (fr) |
| AT (1) | ATE371448T1 (fr) |
| AU (1) | AU753486B2 (fr) |
| BE (1) | BE2016C011I2 (fr) |
| BR (1) | BR9912021A (fr) |
| CA (2) | CA2678722C (fr) |
| CY (4) | CY1107779T1 (fr) |
| CZ (2) | CZ304359B6 (fr) |
| DE (2) | DE122007000055I1 (fr) |
| DK (2) | DK2322174T3 (fr) |
| ES (2) | ES2552639T3 (fr) |
| FR (1) | FR16C0008I2 (fr) |
| HU (1) | HU229383B1 (fr) |
| ID (1) | ID27664A (fr) |
| IL (3) | IL140665A0 (fr) |
| LU (2) | LU91358I2 (fr) |
| NL (2) | NL300290I2 (fr) |
| NO (2) | NO331802B1 (fr) |
| NZ (2) | NZ509260A (fr) |
| PL (1) | PL194604B1 (fr) |
| PT (2) | PT1096932E (fr) |
| RU (3) | RU2450813C2 (fr) |
| SG (1) | SG142116A1 (fr) |
| SI (2) | SI2322174T1 (fr) |
| SK (1) | SK285863B6 (fr) |
| TR (1) | TR200100062T2 (fr) |
| WO (1) | WO2000002543A2 (fr) |
| ZA (1) | ZA200100232B (fr) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR200100062T2 (tr) | 1998-07-10 | 2001-06-21 | Novartis Ag | Valsartan ve kalsiyum kanalı bloklayıcısının anti-hipertensif kombinasyonu |
| ES2373556T3 (es) * | 1998-12-23 | 2012-02-06 | Novartis Ag | Comprimidos de valsartán. |
| CN1172719C (zh) * | 1999-04-28 | 2004-10-27 | 武田药品工业株式会社 | 单纯性视网膜病或前增殖性视网膜病的预防剂、治疗剂、发展抑制剂 |
| EP1867342A1 (fr) * | 1999-07-21 | 2007-12-19 | Takeda Pharmaceutical Company Limited | Agents pour l'amélioration de troubles suite à une défaillance cérébrovasculaire et pour inhiber sa progression |
| SE9903028D0 (sv) * | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
| SK2692002A3 (en) | 1999-08-30 | 2002-07-02 | Aventis Pharma Gmbh | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
| AU2001235364A1 (en) * | 2000-02-25 | 2001-09-03 | Novo-Nordisk A/S | Tetrahydronaphtalene derivatives and their use |
| AU2001235363A1 (en) * | 2000-02-25 | 2001-09-03 | Novo-Nordisk A/S | Mibefradil analogues and their use |
| AU7393801A (en) * | 2000-04-12 | 2001-10-23 | Novartis Ag | Combination of organic compounds |
| DE10018401A1 (de) * | 2000-04-13 | 2001-10-25 | Boehringer Ingelheim Pharma | Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen |
| AR033390A1 (es) * | 2000-08-22 | 2003-12-17 | Novartis Ag | Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes |
| US20060089389A1 (en) | 2000-08-22 | 2006-04-27 | Malcolm Allison | Combination |
| WO2002053147A1 (fr) * | 2000-12-29 | 2002-07-11 | Osmotica Corp. | Composition pharmaceutique destinee au traitement de la maladie cerebrovasculaire cognitive |
| ITMI20010129A1 (it) * | 2001-01-25 | 2002-07-25 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco |
| BR0213357A (pt) * | 2001-10-18 | 2004-10-26 | Novartis Ag | Compostos orgânicos |
| US20030180712A1 (en) | 2002-03-20 | 2003-09-25 | Biostratum Ab | Inhibition of the beta3 subunit of L-type Ca2+ channels |
| EG24716A (en) | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| US20040138306A1 (en) | 2002-07-25 | 2004-07-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure |
| DE10335027A1 (de) * | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
| SE0300988D0 (sv) * | 2003-04-03 | 2003-04-03 | Astrazeneca Ab | New use |
| WO2004110354A2 (fr) | 2003-05-15 | 2004-12-23 | Roskamp Research, Llc | Methode de reduction d'un depot amyloide, neurotoxicite amyloide et microgliose |
| US20070054947A1 (en) * | 2003-05-16 | 2007-03-08 | Cohn Jay N | Pharmaceutical composition comprising valsartan |
| RU2255740C2 (ru) * | 2003-07-02 | 2005-07-10 | Научно-исследовательский институт кардиологии Томского научного центра СО РАМН | Способ подбора дозы дилтиазема для лечения больных постинфарктным кардиосклерозом с недостаточностью кровообращения 2 функционального класса |
| US20050065094A1 (en) | 2003-09-05 | 2005-03-24 | Boehringer Ingelheim International Gmbh | Use of telmisartan for the prevention and treatment of vascular headache |
| WO2005053687A1 (fr) * | 2003-11-25 | 2005-06-16 | Novartis Ag | Combinaison de composes organiques |
| WO2005070462A2 (fr) * | 2004-01-12 | 2005-08-04 | Sepracor, Inc. | Compositions comprenant de la (s)-amlodipine et un bloqueur du recepteur de l'angiotensine, et leurs methodes d'utilisation |
| CN100364532C (zh) * | 2004-09-30 | 2008-01-30 | 江苏恒瑞医药股份有限公司 | 包含氨氯地平和血管紧张素ⅱ受体抑制剂的组合物 |
| ATE526965T1 (de) | 2005-04-15 | 2011-10-15 | Res & Innovation S P A | Verfahren zur prävention, verzögerung oder umkehr von abnormer amyloid-ablagerung |
| GT200600371A (es) * | 2005-08-17 | 2007-03-21 | Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas | |
| GB0520405D0 (en) * | 2005-10-07 | 2005-11-16 | Imp College Innovations Ltd | Biological agents and method |
| BRPI0618371A2 (pt) * | 2005-11-08 | 2011-08-30 | Novartis Ag | combinação de compostos orgánicos |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| RU2329805C2 (ru) * | 2006-08-28 | 2008-07-27 | Илья Николаевич Медведев | Способ стабилизации эндотелиальной выстилки сосудов у больных метаболическим синдромом |
| KR100888131B1 (ko) * | 2006-10-10 | 2009-03-11 | 한올제약주식회사 | 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제 |
| RU2338527C1 (ru) * | 2007-02-26 | 2008-11-20 | Илья Николаевич Медведев | Способ коррекции высокой эндотелиоцитемии у лиц с метаболическим синдромом |
| ES2449594T3 (es) | 2007-10-05 | 2014-03-20 | Alzheimer's Institute Of America, Inc. | Método para reducir deposición amiloide, neurotoxicidad amiloide y microgliosis con enantiomero (-)-nilvadipina |
| CN101433536A (zh) * | 2007-11-12 | 2009-05-20 | 北京瑞康医药技术有限公司 | 含有烟酸氨氯地平和沙坦类药物的治疗组合物 |
| MX2010007281A (es) * | 2007-12-31 | 2010-10-05 | Lupin Ltd | Composiciones farmaceuticas de amlodipina y valsartan. |
| US20100137403A1 (en) * | 2008-07-10 | 2010-06-03 | Scott Malstrom | Method for enhancing cognition or inhibiting cognitive decline |
| RU2382644C1 (ru) * | 2008-11-05 | 2010-02-27 | Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию" | Способ коррекции гипертрофии левого желудочка у больных ибс в сочетании с гипертонической болезнью |
| RU2398581C1 (ru) * | 2009-05-28 | 2010-09-10 | Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс Федерального агентства по высокотехнологичной медицинской помощи (ФГУ РКНПК Росмедтехнологий) | Способ лечения больных гипертрофической кардиомиопатией |
| SI2536396T1 (sl) | 2010-02-16 | 2017-01-31 | KRKA, tovarna zdravil, d.d.,Novo mesto | Postopek za pripravo oralnih trdnih odmernih oblik, ki obsegajo valsartan |
| IT1400309B1 (it) | 2010-05-10 | 2013-05-24 | Menarini Int Operations Lu Sa | Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso. |
| MX341450B (es) | 2011-04-12 | 2016-08-19 | Boryung Pharm | Composicion farmaceutica antihipertensiva. |
| MX2014001556A (es) | 2011-08-12 | 2014-03-31 | Boehringer Ingelheim Vetmed | Composicion farmaceutica de sabor enmascarado. |
| WO2013147137A1 (fr) * | 2012-03-30 | 2013-10-03 | 味の素株式会社 | Agent thérapeutique pour le traitement de l'insuffisance cardiaque |
| CZ2013783A3 (cs) | 2013-10-08 | 2015-04-15 | Zentiva, K. S | Stabilní farmaceutická kompozice obsahující amlodipin a valsartan |
| US20180071272A1 (en) * | 2014-10-23 | 2018-03-15 | The Trustees Of The University Of Pennsylvania | Novel chronotherapy based on circadian rhythms |
| RU2616213C2 (ru) * | 2015-07-10 | 2017-04-13 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Южно-Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ЮУГМУ Минздрава России) | Способ коррекции дисфункции факторов врожденного и адаптивного иммунитета при хронической почечной недостаточности в эксперименте |
| US9877941B2 (en) * | 2015-10-31 | 2018-01-30 | Io Therapeutics, Inc. | Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones |
| CN105287550A (zh) * | 2015-11-19 | 2016-02-03 | 哈尔滨圣吉药业股份有限公司 | 一种缬沙坦/非洛地平复方制剂及其制备方法 |
| BR112022021011A2 (pt) * | 2020-04-17 | 2022-12-27 | Honeybrains Llc | Composições e métodos para tratamento de distúrbios neuropsiquiátricos |
| US20240299405A1 (en) * | 2020-05-28 | 2024-09-12 | Hangzhou Qian Biotechnology Ltd | Application of atp potassium channel modifier in preparation of anti-diabetic nephropathy drug |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4654372A (en) | 1986-01-10 | 1987-03-31 | Warner-Lambert Company | Method for using verapamil for treating stroke |
| GB8608335D0 (en) | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
| ATE134624T1 (de) * | 1990-02-19 | 1996-03-15 | Ciba Geigy Ag | Acylverbindungen |
| NZ242724A (en) | 1991-05-15 | 1994-09-27 | Du Pont | Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker |
| US5492904A (en) | 1991-05-15 | 1996-02-20 | E. I. Du Pont De Nemours And Company | Composition of angiotensin-II receptor antagonists and calcium channel blockers |
| WO1993017682A1 (fr) * | 1992-03-04 | 1993-09-16 | Abbott Laboratories | Antagonistes des recepteurs de l'angiotensine ii |
| RU2104286C1 (ru) * | 1992-07-27 | 1998-02-10 | Пфайзер Инк. | Полипептид или его фармацевтически приемлемые соли |
| US5264447A (en) * | 1992-09-01 | 1993-11-23 | Merck & Co., Inc. | Angiotensin II antagonist |
| US5721263A (en) * | 1993-06-07 | 1998-02-24 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for angiotensin II-mediated diseases |
| CA2125251C (fr) | 1993-06-07 | 2005-04-26 | Yoshiyuki Inada | Composition pharmaceutique pour le traitement des affections mediees par l'angiotensine ii |
| DE59409631D1 (de) * | 1993-07-15 | 2001-02-15 | Hoffmann La Roche | Pharmazeutische Kombination, die einen Hemmer des Renin-Angiotensin-Systems und einen Endothelin-Antagonisten enthält |
| US5889020A (en) * | 1994-02-08 | 1999-03-30 | Ciba Vision Corporation | Treatment of normotensive glaucoma with angiotensin II antagonists |
| BR9507086A (pt) | 1994-03-17 | 1997-09-16 | Ciba Geigy Ag | Tratamento de nefroterapia diabética com valsartan |
| GB9613470D0 (en) | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
| TR200100062T2 (tr) | 1998-07-10 | 2001-06-21 | Novartis Ag | Valsartan ve kalsiyum kanalı bloklayıcısının anti-hipertensif kombinasyonu |
-
1999
- 1999-07-09 TR TR2001/00062T patent/TR200100062T2/xx unknown
- 1999-07-09 SK SK31-2001A patent/SK285863B6/sk not_active IP Right Cessation
- 1999-07-09 CZ CZ2007-647A patent/CZ304359B6/cs not_active IP Right Cessation
- 1999-07-09 AU AU50349/99A patent/AU753486B2/en not_active Expired
- 1999-07-09 CN CNB998097764A patent/CN1234357C/zh not_active Expired - Lifetime
- 1999-07-09 CA CA2678722A patent/CA2678722C/fr not_active Expired - Lifetime
- 1999-07-09 SI SI9931078T patent/SI2322174T1/sl unknown
- 1999-07-09 SI SI9930996T patent/SI1096932T1/sl unknown
- 1999-07-09 NZ NZ509260A patent/NZ509260A/en not_active IP Right Cessation
- 1999-07-09 RU RU2001102585/15A patent/RU2450813C2/ru active Protection Beyond IP Right Term
- 1999-07-09 KR KR1020017000323A patent/KR100550167B1/ko not_active Expired - Fee Related
- 1999-07-09 SG SG200300082-5A patent/SG142116A1/en unknown
- 1999-07-09 PT PT99934647T patent/PT1096932E/pt unknown
- 1999-07-09 RU RU2001102585/15K patent/RU2243768C2/ru active
- 1999-07-09 DE DE200712000055 patent/DE122007000055I1/de active Pending
- 1999-07-09 CN CNA200510072738XA patent/CN1733307A/zh active Pending
- 1999-07-09 ID IDW20010051A patent/ID27664A/id unknown
- 1999-07-09 EP EP07105179A patent/EP1870098A3/fr not_active Withdrawn
- 1999-07-09 JP JP2000558803A patent/JP2002520274A/ja active Pending
- 1999-07-09 DE DE69936992T patent/DE69936992T2/de not_active Expired - Lifetime
- 1999-07-09 WO PCT/EP1999/004842 patent/WO2000002543A2/fr not_active Ceased
- 1999-07-09 NZ NZ527598A patent/NZ527598A/xx not_active IP Right Cessation
- 1999-07-09 EP EP99934647A patent/EP1096932B1/fr not_active Revoked
- 1999-07-09 EP EP10177093.1A patent/EP2322174B1/fr not_active Revoked
- 1999-07-09 DK DK10177093.1T patent/DK2322174T3/en active
- 1999-07-09 PT PT101770931T patent/PT2322174E/pt unknown
- 1999-07-09 IL IL14066599A patent/IL140665A0/xx unknown
- 1999-07-09 PL PL99345897A patent/PL194604B1/pl unknown
- 1999-07-09 CZ CZ20010087A patent/CZ299429B6/cs unknown
- 1999-07-09 DK DK99934647T patent/DK1096932T3/da active
- 1999-07-09 AT AT99934647T patent/ATE371448T1/de active
- 1999-07-09 CA CA002336822A patent/CA2336822C/fr not_active Expired - Lifetime
- 1999-07-09 BR BR9912021-6A patent/BR9912021A/pt not_active IP Right Cessation
- 1999-07-09 ES ES10177093.1T patent/ES2552639T3/es not_active Expired - Lifetime
- 1999-07-09 KR KR10-2004-7011566A patent/KR20040078140A/ko not_active Ceased
- 1999-07-09 HU HU0102828A patent/HU229383B1/hu active Protection Beyond IP Right Term
- 1999-07-09 ES ES99934647T patent/ES2289814T3/es not_active Expired - Lifetime
-
2001
- 2001-01-01 IL IL140665A patent/IL140665A/en unknown
- 2001-01-08 NO NO20010113A patent/NO331802B1/no not_active IP Right Cessation
- 2001-01-09 ZA ZA200100232A patent/ZA200100232B/en unknown
-
2007
- 2007-09-06 LU LU91358C patent/LU91358I2/fr unknown
- 2007-09-10 NL NL300290C patent/NL300290I2/nl unknown
- 2007-10-25 CY CY20071101384T patent/CY1107779T1/el unknown
- 2007-10-30 CY CY200700026C patent/CY2007026I1/el unknown
-
2011
- 2011-07-04 IL IL213926A patent/IL213926A0/en unknown
-
2012
- 2012-03-20 RU RU2012110522/15A patent/RU2012110522A/ru unknown
- 2012-07-03 NO NO2012013C patent/NO2012013I2/no unknown
-
2015
- 2015-10-06 CY CY20151100890T patent/CY1116770T1/el unknown
-
2016
- 2016-03-07 BE BE2016C011C patent/BE2016C011I2/nl unknown
- 2016-03-07 CY CY2016006C patent/CY2016006I1/el unknown
- 2016-03-07 NL NL300800C patent/NL300800I2/nl unknown
- 2016-03-07 FR FR16C0008C patent/FR16C0008I2/fr active Active
- 2016-03-07 LU LU92992C patent/LU92992I2/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LU92992I2 (fr) | Valsartan et amlodipine et leurs sels pharmaceutiquement acceptables | |
| LU93074I2 (fr) | Sacubitril/valsartan, y compris les sels pharmaceutiquement acceptables de celui-ci |